Enfermedad por crioaglutinina del subtipo IgA como manifestación temprana de mieloma múltiple y resolución tras tratamiento con nuevos fármacos anti-mieloma

Chic Acevedo, Carolina; García Torres, Estefanía; Álvarez Rivas, Miguel Ángel.
Med. clín (Ed. impr.) ; 147(11): e63-e64, dic. 2016.
Artículo en Español | IBECS (España) | ID: ibc-158481

Documentos relacionados

  1. Possible role of IL-23 inhibitor in autoimmune hemolytic anemia.
  2. Autoimmune Cytopenias Are Highly Associated with Inborn Errors of Immunity and They May Be the Initial Presentations in Cases without Severe Infections.
  3. Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study.
  4. Case report: Daratumumab treatment in pre-transplant alloimmunization and severe hemolytic anemia.
  5. Fostamatinib for warm antibody autoimmune hemolytic anemia: Phase 3, randomized, double-blind, placebo-controlled, global study (FORWARD).
  6. Ultrastructural analysis of nucleated erythrocyte in patients with autoimmune hemolytic anemia (AIHA).
  7. Cold agglutinin disease revisited: a multinational, observational study of 232 patients.
  8. Sutimlimab: A Complement C1s Inhibitor for the Management of Cold Agglutinin Disease-Associated Hemolysis.
  9. [Warm autoimmune hemolytic anemia accompanied by metachronous double primary cancer].
  10. Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease.